Diagnosing and defining MASLD in people living with chronic hepatitis B

Chronic hepatitis B (CHB) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) are important contributors to the growing worldwide burden of liver disease. There is limited understanding regarding the interaction between CHB and MASLD. This is a consequence of the changing terminology for liver disease, inconsistent application of diagnostic tools, and poor understanding of global populations. In this review, we collate data on the use of diagnostic tests for identifying MASLD and associated liver inflammation or fibrosis in people living with CHB. We advocate for improved consensus on diagnosis, evidence-based monitoring and risk stratification, enhanced access to interventions and reduced health inequity.

Authors

Institutions

Publication Details

Journal
Communications Medicine
Published
2026-05-08
DOI
https://doi.org/10.1038/s43856-026-01383-2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Diagnosing and defining MASLD in people living with chronic hepatitis B

Stuart Flanagan, Richard Gilson, Willem DF Venter, EA Tsochatzis et al.
Communications Medicine
Liver Disease Diagnosis and Treatment
article

Diagnosing and defining MASLD in people living with chronic hepatitis B

Stuart Flanagan, Richard Gilson, Willem DF Venter, EA Tsochatzis, Douglas Macdonald, Nomathemba Chandiwana, Alejandro Arenas-Pinto, Emily Martyn, Jennifer Manne-Goehler, Philippa C. Matthews
article en

Abstract

Chronic hepatitis B (CHB) infection and metabolic dysfunction-associated steatotic liver disease (MASLD) are important contributors to the growing worldwide burden of liver disease. There is limited understanding regarding the interaction between CHB and MASLD. This is a consequence of the changing terminology for liver disease, inconsistent application of diagnostic tools, and poor understanding of global populations. In this review, we collate data on the use of diagnostic tests for identifying MASLD and associated liver inflammation or fibrosis in people living with CHB. We advocate for improved consensus on diagnosis, evidence-based monitoring and risk stratification, enhanced access to interventions and reduced health inequity.

Communications MedicineVol. 6(1)
Brigham and Women's Hospital (US), Harvard University (US), Desmond Tutu HIV Foundation (ZA), University of Cape Town (ZA), Royal Free London NHS Foundation Trust (GB), University of the Witwatersrand (ZA), Central and North West London NHS Foundation Trust (GB), The Francis Crick Institute (GB), Massachusetts General Hospital (US), Immune Regulation (United Kingdom) (GB), University College London (GB)
Wellcome Trust, Francis Crick Institute, Cancer Research UK, National Institute for Health and Care Research, University College London, Medical Research Council
No poverty
Openalex Percentile: Top 6%
Liver Disease Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Diagnosing and defining MASLD in people living with chronic hepatitis B — Stuart Flanagan, Richard Gilson, et al. · Communications Medicine (2026) | TGRS Research Map | TGRS